Citation

Hjemdal O, Hagen R, Solem S, Nordahl H, Kennair LEO, Ryum T, Nordahl HM, Wells A. Cogn. Behav. Pract. 2017; 24(3): 312-318.

Copyright

(Copyright © 2017, Association for Advancement of Behavior Therapy, Publisher Elsevier Publishing)

DOI

10.1016/j.cbpra.2016.06.006

PMID

unavailable

Abstract

This open trial investigated the transdiagnostic effects of metacognitive therapy (MCT) in patients with severe major depressive disorder and comorbid psychiatric disorder. Ten patients were treated with MCT over 10 sessions and were assessed with measures of depression, anxiety, rumination, and metacognitions at pre- and posttreatment and at 6 months follow-up. None of the patients were diagnosed as depressed at posttreatment, and of the initial 21 total diagnoses at pretreatment only 3 diagnoses remained at postintervention. The effect sizes were large for symptoms of depression, rumination, and worry. At 6 months follow-up standardized recovery criteria on the BDI showed that 70% were recovered, 20% improved, and 10% unchanged. The results indicate that MCT was associated with high rates of transdiagnostic improvement.

Language: en

Keywords

anxiety; comorbidity; depression; metacognitive therapy; rumination